Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
2. Valmont Industries, Inc.
16.2% sales growth and 11.86% return on equity
Valmont Industries, Inc. produces and sells fabricated metal products in the United States, Australia, Denmark, and internationally.
Valmont Industries, Inc.'s sales growth this year is expected to be 11% and 4.2% for next year.
Year-on-year quarterly revenue growth grew by 16.8%, now sitting on 2.9B for the twelve trailing months.
Valmont Industries, Inc.'s sales growth for the next quarter is 16.2%. The company's growth estimates for the current quarter and the next is 6.5% and 16%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 11.86%.
Volatility
Valmont Industries, Inc.'s last day, last week, and last month's current volatility was 1.10%, 1.31%, and 1.45%, respectively.
Valmont Industries, Inc.'s current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 2.61% (day), 2.16% (last week), and 2.74% (last month), respectively.
Valmont Industries, Inc.'s Stock Yearly Top and Bottom Value
Valmont Industries, Inc.'s stock is valued at $232.73 at 23:22 EST, below its 52-week high of $251.63 and way above its 52-week low of $98.00.
Valmont Industries, Inc.'s Moving Average
Valmont Industries, Inc.'s value is below its 50-day moving average of $238.62 and way higher than its 200-day moving average of $188.57.3. Maiden Holdings, Ltd.
179.6% sales growth and 8.07% return on equity
Maiden Holdings, Ltd., through its subsidiaries, provides property and casualty reinsurance solutions to regional and specialty insurers in Europe, the United States, and internationally.
Maiden Holdings, Ltd.'s sales growth this year is anticipated to be 231.6% and a negative 0% for next year.
Year-on-year quarterly revenue growth declined by 33.8%, now sitting on 184.12M for the twelve trailing months.
Maiden Holdings, Ltd.'s sales growth for the next quarter is 179.6%. The company's growth estimates for the ongoing quarter and the next is a negative 0% and negative 0%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 8.07%.
Volatility
Maiden Holdings, Ltd.'s last day, last week, and last month's current volatility was 4.37%, 2.39%, and 2.46%, respectively.
Maiden Holdings, Ltd.'s current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 7.06% (day), 5.11% (last week), and 5.13% (last month), respectively.
Maiden Holdings, Ltd.'s Stock Yearly Top and Bottom Value
Maiden Holdings, Ltd.'s stock is valued at $3.43 at 23:22 EST, below its 52-week high of $3.66 and way above its 52-week low of $0.78.
Maiden Holdings, Ltd.'s Moving Average
Maiden Holdings, Ltd.'s worth is above its 50-day moving average of $3.12 and way higher than its 200-day moving average of $2.24.4. Halozyme Therapeutics, Inc.
39.6% sales growth and 106.32% return on equity
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, and internationally.
Halozyme Therapeutics, Inc.'s sales growth this year is expected to be 46.1% and 49.7% for next year.
Year-on-year quarterly revenue growth grew by 126.8%, now sitting on 267.59M for the twelve trailing months.
Halozyme Therapeutics, Inc.'s sales growth for the next quarter is 39.6%. The company's growth estimates for the current quarter and the next is 875% and 94.7%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 106.32%.
Volatility
Halozyme Therapeutics, Inc.'s last day, last week, and last month's current volatility was 3.56%, 1.24%, and 1.58%, respectively.
Halozyme Therapeutics, Inc.'s current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 3.32% (day), 2.84% (last week), and 3.52% (last month), respectively.
Halozyme Therapeutics, Inc.'s Stock Yearly Top and Bottom Value
Halozyme Therapeutics, Inc.'s stock is valued at $45.95 at 23:22 EST, way under its 52-week high of $56.40 and way above its 52-week low of $16.55.
Halozyme Therapeutics, Inc.'s Moving Average
Halozyme Therapeutics, Inc.'s value is higher than its 50-day moving average of $44.23 and way higher than its 200-day moving average of $39.74.5. Abbott Laboratories
56.3% sales growth and 13.91% return on equity
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide.
Abbott Laboratories's sales growth this year is expected to be 22% and a negative 0.4% for next year.
Year-on-year quarterly revenue growth grew by 28.7%, now sitting on 34.61B for the twelve trailing months.
Abbott Laboratories's sales growth for the next quarter is 56.3%. The company's growth estimates for the ongoing quarter and the next is 95.4% and 122.8%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 13.91%.
Volatility
Abbott Laboratories's last day, last week, and last month's current volatility was 0.94%, 0.44%, and 0.89%, respectively.
Abbott Laboratories's current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 1.32% (day), 1.44% (last week), and 1.77% (last month), respectively.
Abbott Laboratories's Stock Yearly Top and Bottom Value
Abbott Laboratories's stock is valued at $120.90 at 23:22 EST, below its 52-week high of $128.54 and way higher than its 52-week low of $83.52.
Abbott Laboratories's Moving Average
Abbott Laboratories's worth is above its 50-day moving average of $119.46 and above its 200-day moving average of $113.43.Previous days news about Abbott Laboratories
According to Bloomberg Quint on Wednesday, 14 April, "U.S. regulators this month authorized quick tests made by Abbott Laboratories and Quidel Corp. for use at home without a prescription, opening the door to their wide availability at retail stores."